Pfizer Inc. (NYSE:PFE) Shares Acquired by Allen Capital Group LLC

Allen Capital Group LLC boosted its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 13.9% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 143,036 shares of the biopharmaceutical company's stock after buying an additional 17,454 shares during the quarter. Allen Capital Group LLC's holdings in Pfizer were worth $3,625,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Brighton Jones LLC boosted its holdings in Pfizer by 1,282.4% in the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock valued at $17,677,000 after purchasing an additional 618,117 shares during the period. Revolve Wealth Partners LLC boosted its holdings in Pfizer by 12.5% in the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock valued at $498,000 after purchasing an additional 2,087 shares during the period. Madison Investment Advisors LLC purchased a new stake in shares of Pfizer during the 4th quarter valued at $5,360,000. Creative Financial Designs Inc. ADV raised its position in shares of Pfizer by 4.7% during the 4th quarter. Creative Financial Designs Inc. ADV now owns 44,882 shares of the biopharmaceutical company's stock valued at $1,191,000 after buying an additional 2,023 shares in the last quarter. Finally, Cibc World Markets Corp raised its position in shares of Pfizer by 17.3% during the 4th quarter. Cibc World Markets Corp now owns 902,242 shares of the biopharmaceutical company's stock valued at $23,936,000 after buying an additional 133,084 shares in the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Trading Down 0.3%

PFE stock traded down $0.08 during mid-day trading on Friday, reaching $24.51. The company had a trading volume of 17,558,966 shares, compared to its average volume of 45,621,094. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.26 and a quick ratio of 0.96. The company has a market capitalization of $139.32 billion, a PE ratio of 17.76, a price-to-earnings-growth ratio of 0.90 and a beta of 0.58. The firm has a 50 day moving average of $24.02 and a 200 day moving average of $24.75. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The business had revenue of $13.72 billion for the quarter, compared to the consensus estimate of $14.43 billion. During the same period in the prior year, the firm earned $0.82 EPS. The company's revenue for the quarter was down 7.8% compared to the same quarter last year. On average, equities analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 25th. This represents a $1.72 annualized dividend and a dividend yield of 7.02%. Pfizer's payout ratio is presently 124.64%.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the company. Leerink Partners cut their price objective on Pfizer from $28.00 to $26.00 and set a "market perform" rating for the company in a report on Wednesday, April 30th. Redburn Atlantic cut their price objective on Pfizer from $29.00 to $27.00 and set a "neutral" rating for the company in a report on Wednesday, April 30th. HSBC lowered their price target on shares of Pfizer from $27.00 to $26.00 and set a "buy" rating for the company in a research note on Monday, May 19th. UBS Group boosted their price target on shares of Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research note on Wednesday, April 30th. Finally, Jefferies Financial Group boosted their price target on shares of Pfizer from $32.00 to $33.00 and gave the stock a "buy" rating in a research note on Wednesday, May 21st. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating, six have assigned a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat, Pfizer has an average rating of "Hold" and a consensus target price of $28.55.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.